Table 1.

Vaccination with live attenuated rVSV-S vaccine protects mice from challenge with SARS-CoV

Intervention group	Mouse number	Pre-challenge neutralizing antibody titer in serum (log2)a	Virus titer in lungsb	Mean maximum change in weight (on day 7)c
SARS-CoV	1	5.5	≤ 1.5d
	2	7.0	≤ 1.5
	3	7.7	≤ 1.5
	4	5.3	≤ 1.5
			Mean ≤ 1.5	+ 0.5%
rVSV-S	5	≤ 2e	4.2
	6	3	3.7
	7	3	3.4
	8	3	≤ 1.5
			Mean 3.2 ± 0.60	+0.5%
rVSV	9	≤ 2	7.7
	10	≤ 2	7.4
	11	≤ 2	7.9
	12	≤ 2	7.9
			Mean 7.8 ± 0.12	−10%

^aLog transformed reciprocal mean SARS-CoV specific neutralizing antibody titer

^bViral titers expressed as log₁₀TCID₅₀/g tissue, p ≤ 0.0001 SARS-CoV compared to rVSV control and p = 0.0003 for rVSV-S compared to rVSV control, day 2 post challenge

^cExpressed as percent change in weight from weight on day of challenge (d 0)

^dVirus not detected, this value is the lower limit of virus detection

^eNeutralizing antibody not detected, this value is at the lower limit of detection